Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biomatrix (BXM) Looking Great -- Ignore unavailable to you. Want to Upgrade?

To: John McCarthy who wrote (173)	11/9/1997 7:46:00 PM
From: John McCarthy	Read Replies (1) \| Respond to of 569

BIOX-Est. $2.28 vs $1.36 for 98 vs 97 E.P.S. respectively 67% E.P.S Growth 1997 vs. 1998 quarterly E.P.S. Biomatrix, Inc. ---------------------------------------------- E.P.S. 1997 vs 1998 ---------------------------------------------- 97 98 -------- ------- 1ST .23 .19 2ND .11 .60 3RD .85 .50 4TH .17 .99 -------- ------- Year 1.36 2.28 -------- ------- -------- ------- % Change 67% -------- ------- -------- ------- Notes: ---------------------------------------------- 1 ---------------------------------------------- 2nd qtr. 98 anticipates $5.0 mil. license payment from Collagen for Hylaform - USA. As of right now:FDA HAS NOT approved Hylaform ---------------------------------------------- 2 ---------------------------------------------- 3th qtr. 97 included a $12.0 mil. payment from AHP for Synvisc. ---------------------------------------------- 3 ---------------------------------------------- 4th qtr. 98 includes 6.0 mil. license payments from AHP as per BIOX 10Q of Sept. 1997. for Synvisc. ---------------------------------------------- 4 ---------------------------------------------- Total product sales (Synvisc/Hylaform) anticipated to be about $61.0 mil. in 1998. Regards, John McCarthy